DK0945465T3 - Antagonistiske monoklonale antistoffer mod humant CD40 - Google Patents

Antagonistiske monoklonale antistoffer mod humant CD40

Info

Publication number
DK0945465T3
DK0945465T3 DK99104709T DK99104709T DK0945465T3 DK 0945465 T3 DK0945465 T3 DK 0945465T3 DK 99104709 T DK99104709 T DK 99104709T DK 99104709 T DK99104709 T DK 99104709T DK 0945465 T3 DK0945465 T3 DK 0945465T3
Authority
DK
Denmark
Prior art keywords
antibodies
antibody
cells
treat
insect cells
Prior art date
Application number
DK99104709T
Other languages
Danish (da)
English (en)
Inventor
Boer Mark De
Leah B Conroy
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27360277&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0945465(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US07/910,222 external-priority patent/US5397703A/en
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of DK0945465T3 publication Critical patent/DK0945465T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK99104709T 1992-07-09 1993-07-08 Antagonistiske monoklonale antistoffer mod humant CD40 DK0945465T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US07/910,222 US5397703A (en) 1992-07-09 1992-07-09 Method for generation of antibodies to cell surface molecules
US08/015,147 US5869050A (en) 1992-07-09 1993-02-09 Methods of blocking T-cell activation using anti-B7 monoclonal antibodies
US08/070,158 US5677165A (en) 1992-07-09 1993-05-28 Anti-CD40 monoclonal antibodies capable of blocking B-cell activation
PCT/US1993/006432 WO1994001547A2 (fr) 1992-07-09 1993-07-08 Procede permettant de produire des anticorps contre des molecules de surface des cellules

Publications (1)

Publication Number Publication Date
DK0945465T3 true DK0945465T3 (da) 2007-01-15

Family

ID=27360277

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99104709T DK0945465T3 (da) 1992-07-09 1993-07-08 Antagonistiske monoklonale antistoffer mod humant CD40

Country Status (5)

Country Link
EP (3) EP0651797B1 (fr)
AT (2) ATE258595T1 (fr)
DE (2) DE69333403T2 (fr)
DK (1) DK0945465T3 (fr)
ES (1) ES2273452T3 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
WO2001034649A2 (fr) * 1999-11-09 2001-05-17 Chiron Corporation Compositions et methodes de traitement de maladies auto-immunes et des rejets de greffon
AU2001259106A1 (en) * 2000-04-19 2002-02-18 Tanox, Inc. CD40 antagonists for use in treating psoriasis and other inflammatory skin conditions
US7063845B2 (en) 2000-04-28 2006-06-20 Gemini Science, Inc. Human anti-CD40 antibodies
WO2001083755A2 (fr) * 2000-04-28 2001-11-08 La Jolla Institute For Allergy And Immunology Anticorps humains anti-cd40, et leurs procedes de production et d'utilisation
DE60143535D1 (de) * 2000-10-02 2011-01-05 Novartis Vaccines & Diagnostic Humane antikörper gegen cd40
CA2658221C (fr) 2001-04-27 2012-11-27 Kyowa Hakko Kirin Co., Ltd. Anticorps monoclonal anti-cd40
DE10132308A1 (de) * 2001-07-06 2003-01-30 Aventis Behring Gmbh Kombinationspräparat zur Therapie von immunologischen Erkrankungen
WO2003028809A1 (fr) * 2001-10-02 2003-04-10 Chiron Corporation Procede pour traiter la malignite de lymphocytes b
WO2003029296A1 (fr) * 2001-10-02 2003-04-10 Chiron Corporation Anticorps humains diriges contre le cd40
WO2006073443A2 (fr) * 2004-04-27 2006-07-13 Novartis Vaccines And Diagnostics, Inc. Anticorps monoclonaux anti-cd40 antagonistes et leurs methodes d'utilisation
EP1854810A1 (fr) 2006-05-09 2007-11-14 PanGenetics B.V. Anticorps monoclonal anti CD40 humain déimmunisé et antagoniste dérivé de l'anticorps ch5D12
EP3355921A4 (fr) * 2015-09-30 2019-05-22 Janssen Biotech, Inc. Anticorps antagonistes se liant spécifiquement au cd40 humain et procédés d'utilisation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992000092A1 (fr) * 1990-07-02 1992-01-09 Bristol-Myers Squibb Company Ligand pour recepteur a cd28 sur des lymphocytes b et procedes

Also Published As

Publication number Publication date
ATE339451T1 (de) 2006-10-15
DE69333403D1 (de) 2004-03-04
DE69334064T2 (de) 2007-05-24
EP0945465B1 (fr) 2006-09-13
EP0945465A1 (fr) 1999-09-29
EP1834671A2 (fr) 2007-09-19
DE69333403T2 (de) 2004-11-11
ATE258595T1 (de) 2004-02-15
ES2273452T3 (es) 2007-05-01
EP0651797B1 (fr) 2004-01-28
EP1834671A3 (fr) 2013-05-22
EP0651797A1 (fr) 1995-05-10
DE69334064D1 (de) 2006-10-26

Similar Documents

Publication Publication Date Title
WO1994001547A3 (fr) Procede permettant de produire des anticorps contre des molecules de surface des cellules
DK0945465T3 (da) Antagonistiske monoklonale antistoffer mod humant CD40
Warner et al. Bone marrow graft rejection as a function of antibody-directed natural killer cells.
TW222279B (fr)
DE69128253T2 (de) Bispezifische antikörper, verfahren zu ihrer herstellung und deren verwendungen
DE69636748D1 (de) Bispezifischer antikörper zur effektiven behandlung von b-zell lymphomen und zellinien
EP0722463A4 (fr) Procede et composition destines a la modulation de la reponse immune d'un hote par rapport aux allergenes
NL990008I2 (nl) CD#2#5 bindende molekulen.
DE59209079D1 (de) Monoklonale Antikörper gegen humane Pankreas-Inselzellen
JPH10505325A (ja) 治療剤としてのｔ細胞に対する抗体
Murphy et al. CD40 stimulation promotes human secondary immunoglobulin responses in HuPBL-SCID chimeras
WO1995034581A1 (fr) Inhibition d'anticorps humains xenogeniques et allogeniques pour reduire le rejet de xenogreffe ou d'allogreffe chez des receveurs humains
DE3851492D1 (de) Ein gattungsspezifisches Listeria-Antigen, identifiziert durch monoklonale Antikörper.
PL314414A1 (en) Antiidiotypic antibodies capable to induce an immunological response in respect to the receptor of epidermis growth factor
Dennert et al. Induction of bone marrow allograft rejection and hybrid resistance in nonresponder recipients by antibody: is there evidence for a dual receptor interaction in acute marrow graft rejection?
FI20095269A (fi) Lymfosyyttien sitoutumiseen vaikuttava ihmisen endoteelisolun molekyyli
Kremmer et al. Induction and suppression of anti-antibodies to syngeneic T cell-binding antibodies in mice
Thierfelder et al. Immunosuppression by Fc region‐mismatched anti‐T cell antibody treatment
EP0380018A3 (en) Rat monoclonal antibodies directed against human antigens and processes for preparation thereof
Else et al. Antibody isotype responses to Trichuris infection in humanized SCID mice
Mysliwietz et al. Long‐lasting unresponsiveness to polyclonal T cell‐binding immunoglobulins
GRONOWICZ et al. Quantity and Quality of Anti‐Hapten Antibodies in Normal and in T Cell‐Deprived Mice Studied at the Cellular Level
STRoNG et al. Anti-idiotype antibody in the primate
Mateo et al. A different method for obtaining an engineered murine antibody, that recognizes epidermal growth factor receptor, with reduced immunogenicity
De Boer et al. Method for generation of antibodies to cell surface molecules